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Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of
amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD). Early biomarkers of ARIA
represent an important challenge to ensure safe and beneficial effects of immunothera-
pies, given that different promising clinical trials in prodromal and subjects at risk for AD are
underway. The recent demonstration that cerebrospinal fluid (CSF) anti-Aβ autoantibodies
play a key role in the development of the ARIA-like events characterizing cerebral amyloid
angiopathy-related inflammation generated great interest in the field of immunotherapy.
Herein, we critically review the growing body of evidence supporting the monitoring of
CSF anti-Aβ autoantibody as a promising candidate biomarker for ARIA in clinical trials.
Keywords: cerebral amyloid angiopathy related inflammation, iCAβ International Network, Alzheimer’s dis-
ease, cerebrospinal fluid biomarker, amyloid-related imaging abnormalities, Aβ disease modifying therapies,
immunotherapy, anti-amyloid antibody clinical trials
Introduction
Biomarkers for the stratification, follow-up and monitoring of the safe and effective therapeutic
response of amyloid-beta (Aβ) disease-modifying therapies (DMT) represent a research priority
in Alzheimer’s disease (AD) (1).
Immunotherapy trials, in particular, have underlined the urgent need of safety biomarkers to
avoid, or at least enable the early detection of the severe side effects of treatment termed amyloid-
related imaging abnormalities (ARIA) (2). There are two types of ARIA: ARIA-E, characterized
by the magnetic resonance imaging (MRI) evidence of vasogenic edema (VE) and/or sulcal effu-
sion on fluid-attenuated inversion recovery (FLAIR), as hallmarks of inflammation at the level
of the affected vessels; and ARIA-H, characterized by signal of hemosiderin deposits involving
microhemorrhages (MHs) and superficial siderosis on T2*-weighted gradient echo (T2*-GRE) or
susceptibility-weighted imaging (SWI), as hallmarks of cerebral amyloid angiopathy (CAA) (3)
(Figures 1A,B).
Even if the acronym ARIA was initially referred to specifically describe the MRI abnormalities
of bapineuzumab (2, 4–6), the first monoclonal antibody employed in clinical trial, the term is
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FIGURE 1 | Similarities between immunotherapy-induced ARIA and
spontaneous ARIA-like events in CAA-ri. Upper row. Axial brain MRI
revealing ARIA-E (A) and ARIA-H [(B), arrow] in one AD patient treated with
bapineuzumab. Reproduced with permission from Ref. (3). Lower row. Axial
brain MRI revealing spontaneous ARIA-E (C) and ARIA-H [(D), arrow]
occurring in one CAA-ri patient from the “The inflammatory Cerebral Amyloid
Angiopathy and Alzheimer’s disease βiomarkers (iCAβ) International Network
(20, 50).” Images (A,C) represent FLAIR-MRI sequences; (B,D) represent
T2*-GRE sequences.
currently used to define the clinical–radiological side effects sub-
sequently reported with almost all the immunotherapy strategies
tested (7–12).
Today, no early biomarker able to predict the incipient occur-
rence of an ARIA has been already included in clinical trials.
However, the current FDA guidelines for enrolling patients in
studies assessing DMT requireMRI evaluation, recommending to
exclude patientswith5MHs andwith any evidence of superficial
siderosis or prior parenchymal hemorrhage (3, 6). Nevertheless,
MHs on MRI are relatively non-specific, reflecting a variety of
pathologic conditions. MRI could thus be particularly helpful for
the detection of the acute/subacute course of ARIA, but it could
fail to predict patients at high risk to develop incipient occurrence
of these events, both at the baseline and during the therapeutic
follow-up (13–18).
The ARIA issue recently generated increasing interest after
the very promising data for the Phase 1b study of aducanumab
(NCT01677572) were presented at the 12th AD/PD Meeting in
Nice (19) and at the Alzheimer’s Association International Con-
ference (AAIC 2015) inWashington (12). This drug demonstrated
a statistically significant cognitive improvement in patients with
prodromal ormild AD, together with a dose- and time-dependent
reduction of deposited Aβ on amyloid-PET. Aducanumab, how-
ever, revealed an incidence of immunotherapy-related ARIA in
the 55% of patients, particularly in the high-dose and APOE"4
carriers arm, associated with a 35% of ARIA drop-outs due to the
development of these side effects (19).
The recent discovery that ARIA-like events in CAA-related
inflammation (CAA-ri) are mediated by increased anti-Aβ
autoantibodies in the CSF, has sensibly increased the understand-
ing of the etiological mechanisms of ARIA. CAA-ri has thus been
proposed as a human spontaneous model of the drug-induced
ARIA in AD (15–17).
Starting from this background, in this review we critically
discuss the growing body of evidence supporting the dosage of
CSF anti-Aβ autoantibody as a promising candidate biomarkers
for ARIA in clinical trials (13, 15–17, 20, 21).
Immunotherapy-Induced ARIA
Trials in AD and natural history studies have suggested that
the following all contribute to the development of ARIA: 1)
the severity of Aβ deposition (e.g., greater in advanced stages
of the disease), 2) the degree of CAA in an already impaired
vasculature, 3) the APOE"4 allele dose, and 4) the dose of drug
administered.
In human clinical trials, although the mechanisms leading to
ARIA are not yet fully elucidated, it is well demonstrated that
increased drug dosage clearly augments the risk to develop ARIA
(4, 11, 12, 19). Another interesting aspect is that APOE"4 car-
riers, with higher parenchymal and vascular Aβ load, are more
vulnerable to ARIA, due to the larger antibody-enhancement shift
in Aβ. Consistently, the analyses of the two phase III trials of
bapineuzumab showed a greater incidence of ARIA in associa-
tion with the number of APOE"4 alleles, increasing from 11.4%
in APOE"4 heterozygotes to 27.3% in APOE"4 homozygotes.
Interestingly, APOE"4 carriers represented the well-responder
group of patients, showing a dose-related reduction of CSF tau
and phospho-tau and a decreased rate of Aβ accumulation on
amyloid-PET after treatment with bapineuzumab (4, 6, 22), gan-
tenerumab (11), and aducanumab (12, 19).
A retrospective revision of all MRI scans of patients included
in the bapineuzumab trials identified an even larger number of
ARIA cases (35%) than those previously described (17%), in line
with the recent data emerged for aducanumab (55%). Particularly,
ARIA-E were reported as the most common abnormalities, while
nearly half of the ARIA-E positive cases also developed ARIA-
H, often colocalized in the same brain regions. In addition, it
has been shown that these abnormalities tended to occur early
in the course of treatment, with most occurring between the first
and third infusion. ARIA can present with relevant neurological
signs, characterized by headache, confusion, and neuropsychi-
atric symptoms. Patients, however, may also experience mildly
symptomatic or asymptomatic ARIA, rapidly resolving with the
discontinuation of treatment (3, 4, 6, 11, 12, 19).
Of note, ARIA have always been reported to be paradoxically
more represented in patients treated at the higher, but more
effective, dosages of the administered therapeutic antibody (2, 4,
6–12, 19), thus dramatically increasing the interest in biomarkers
for understanding, predicting, and monitoring these potential
hazards (14, 15, 17).
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Spontaneous ARIA-Like Events
In 2013, the discovery that the typical MRI findings of VE (ARIA-
E) and multiple area of MHs and/or superficial siderosis (ARIA-
H) characterizing the acute phase of CAA-ri represent a varia-
tion of drug-induced ARIA has generated great interest in the
field of immunotherapy (16). Following this first evidence, sev-
eral subsequent studies have clearly confirmed the clinical and
radiological similarities. CAA-ri is characterized by symptomatic
or mildly symptomatic acute/subacute neurological signs, mainly
headache, mental confusion, psychiatric symptoms, dizziness,
and focal signs. Moreover, like in AD trials, the MRI features
are represented by asymmetrical and bilateral VE involving the
posterior cortical/subcortical white matter, and by diffuse MHs
or signs of cortical superficial siderosis (Figures 1C,D). Addi-
tionally, as for immunotherapy-induced ARIA, the APOE4 geno-
type is overrepresented in CAA-ri patients (16, 23–30). Another
interesting finding is that CAA-ri patients are typically very well
responsive to immunosuppressive therapy if diagnosed and med-
icated promptly, rarely reporting the occurrence of successive
relapses (20).
Of note, spontaneous ARIA-like events have been recently
identified in prodromal (21, 31) and established AD (32), and in
one case, the development of ARIA has been reported as a possible
trigger for rapidly progressive dementia (21).
Interestingly, spontaneous ARIA and CAA-ri have been also
described in familial forms of AD (FAD), i.e., in AβPP duplica-
tion carriers (33), in presenilin 1-associated FAD (I202F PSEN1
mutation) (34), and in two siblings carrying the P284S PSEN1
mutation (35). Recognition that ARIA may arise spontaneously
during the course of FAD is a particular timely and important
observation that further reinforces the parallelism between iatro-
genic and spontaneous ARIA, given the immunotherapy trials for
FAD underway.
Anti-Aβ Antibodies as Biomarker for ARIA
The lack of reliable techniques for the detection of anti-Aβ autoan-
tibodies have so far led to contradictory results, showing a reduced
(36–38), partially modified (39), unchanged (40, 41), or even
increased amount in AD patients (42, 43). A possible explanation
is that these studies were conducted in plasma or serum, while
their CSF levels have never been clearly explored before.
The recent development of an ultra-sensitive technique able to
detect the very low concentration of anti-Aβ autoantibodies in
the human CSF has sensibly increased the understanding of their
physio-pathological functions (16). CSF anti-Aβ autoantibodies
have been demonstrated to play a key role in the etiopathogenesis
of ARIA-like in CAA-ri and, today, CAA-ri is widely accepted as
a human spontaneous model of the therapeutic-induced ARIA
(15–17).
First, like in immunotherapy, the acute phase of CAA-ri is char-
acterized by a specific immune reaction mediated by an increased
amount of autologous CSF antibodies against the perivascular
deposited Aβ typical of CAA (13, 16, 21, 44–46). Although
observed in a single case study, autoantibodies have been found to
be intrathecally produced and specifically increased only in CSF,
while no changes has been found in the plasma, thus reflecting
the immune/inflammatory mechanisms restricted to the brain
(13). However, considering the less invasive procedure compared
to CSF, further investigations in a larger population will be of
certain interest. Second, the temporal relationship between anti-
Aβ autoantibody levels and clinical and radiological improvement
of CAA-ri strongly supports they are a specific trait of the VE and
MHs processes (ARIA-like events) (13, 16, 21, 46). Third, like in
AD-treated patients, the increased CSF level of Aβ40 and Aβ42,
the decreased amyloid-PET uptake, and the higher amounts of
anti-Aβ autoantibodies indicate a transient massive drainage of
Aβ from the brain and vascular deposits to its soluble forms
(18, 20, 31, 47). Furthermore, in line with data from passive
immunization (8, 48), a reduction of both autoantibodies and
neurodegenerativemarkers tau and P-tau in the CSF has also been
demonstrated following the clinical and radiological remission of
the acute phase of the disease (16, 21). Fourth, the levels of anti-
Aβ autoantibodies specifically discriminateCAA-ri from sporadic
CAA without inflammation, other non-CAA inflammatory and
autoimmune disorders or healthy controls (13, 16, 20, 21). Fifth,
anti-Aβ autoantibodies have been suggested as a possible early
predictor of CAA-ri recurrence (20).
Such insights have definitively pointed out the dosage of CSF
anti-Aβ autoantibodies as a very promising candidate biomarker
for the diagnosis, monitoring and management of ARIA. Cur-
rently, although the validation of cut-offs for clinical diagnostic
purposes is still ongoing, the dosage of CSF anti-Aβ autoantibod-
ies in CAA-ri is already accepted as a valid support in clinical
practice (49).
Future Directions in Immunotherapy Trials
The recognition that CSF anti-Aβ autoantibodies represent a valid
biomarker in the diagnosis of CAA-ri paves the way for new
avenues in immunotherapy of AD. Studies aiming to quantify
the amount of naturally occurring anti-Aβ autoantibodies in AD
patients enrolled in clinical trials should thus be taken in serious
consideration (49).
The inflammatory Cerebral Amyloid Angiopathy and
Alzheimer’s disease βiomarkers (iCAβ) International Network, a
World-Wide Consortium aimed to the discovery and validation
of biomarkers of ARIA in the largest cohort of CAA-ri today
available, represents a leading authority in the field (50).
Here is an example of the different critical information that
may derive by the measurement of CSF anti-Aβ autoantibodies
as promising candidate biomarker for ARIA.
Patient Engagement Biomarker
The baseline level of CSF anti-Aβ autoantibodies in AD and
healthy subjects is currently unknown. A key area for future
studies will be to explore the levels and time course of CSF
anti-Aβ autoantibodies at the baseline (before treatment) and
during immunotherapy. Of note, the high prevalence of APOE"4
carriers and the co-localization of MHs and VE in CAA-ri
(20) further strength the indication to dose anti-Aβ autoan-
tibodies as a potential biomarker to identify those patients at
higher risk of ARIA. Notably, these findings will be of direct
relevance also for CAA, since the first phase I immunotherapy
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trial (ponezumab) for sporadic CAA has recently been launched
(NCT01821118).
Drug Tailoring Biomarker
The monitoring of CSF anti-Aβ antibodies (both therapeutically
administered and naturally produced) may allow personalizing
treatment for a greater clinical effect, minimizing the occurrence
of ARIA side effects, in order to maintain a putative “therapeutic
window” for the safe clearance of vascular Aβ. This may be par-
ticularly true for patients at high risk for ARIA (APOE"4 carriers
and/or high CSF autoantibody at the baseline). This may also
explain the lack of efficacy of previous immunotherapy trials com-
pared to aducanumab. The dosage of the therapeutic antibody has
often been limited due to the concerns ofARIA side-effect, leading
to the exclusion of patients from the opportunity to be treated and
the continuous adjustment of the therapeutic protocols.
Safety Prediction and Drug Engagement
Biomarker
The identification of cut-off for ARIA-like events has been
demonstrated to be a valid diagnostic biomarker in CAA-ri. The
measurement of theCSF anti-Aβ antibodies titer in patients devel-
oping ARIA could allow establishing similar reference values for
the prediction or, at least, the early diagnosis of these events during
immunotherapy of AD. This could permit the management of
treatment, e.g., reducing the dosage or delaying further infusions
in patients at risk for ARIA. This could be particularly important
between the second and third drug administration, since the
majority of ARIA have been reported during this period (2, 4, 6,
8). Moreover, the monitoring of CSF anti-Aβ antibodies, together
with the proof of reduced Aβ accumulation on amyloid-PET
(11, 12, 22) and the increased level of CSF Aβ, could be proposed
as an additional biomarker to monitor drug efficacy and for a
better interpretation of the trial outcomes.
Biomarker for ARIA Remission at Follow-up
In the case of ARIA occurrence, an early diagnosis will allow
a prompt medication, e.g., steroid administration, thus avoid-
ing the exclusion of these patients from trials. Furthermore,
the return of CSF anti-Aβ antibodies below a putative cut-off
level (still to be established) could help clinicians in confirming
the effective remission of ARIA, as efficiently demonstrated in
CAA-ri (16).
Conclusions
In the last decade, ARIA have severely limited the development
of DMT. The validation of anti-Aβ autoantibodies biomarker for
the monitoring and prediction of ARIA could have critical impli-
cations to avoid the occurrence of these serious side-effects. Anti-
Aβ autoantibodies may offer a unique possibility to explore the
relationships between Aβ clearance and the outcomes of clinical
trials, increasing the chances for developing innovative DMT.
The monitoring of CSF anti-Aβ autoantibodies could help
personalized treatment. The stratification of patients based on the
risk to develop ARIA could allow their allocation in the right
dosage arm in order to obtain the best therapeutic window for
each specific treatment and study. Of note, since we are moving
to larger and longer prevention trials in prodromal and subjects
at risk for AD, based on the selective enrollment of patients
with positive CSF and/or amyloid-PET uptake (Table 1), this is
a particularly timely issue that could potentially increase the risk
TABLE 1 | Use of CSF and amyloid-PET biomarkers in current immunotherapy trials of Alzheimer’s disease and cerebral amyloid angiopathy (update –
September 2015).
Drug Condition Trial phase Biomarker use Clinical trial
government
identifierCSF Amyloid PET
Solanezumab (A4 study,
Expedition3, ExpeditionEXT)
Asymptomatic AD or mild to
moderate AD
III Outcome evaluation Inclusion and outcome
evaluations
NCT02008357
NCT01900665
NCT01127633
Gantenerumab Prodromal or mild AD III Inclusion and outcome
evaluations
Inclusion and outcome
evaluations
NCT02051608
NCT01224106
Gantenerumab and
Solanezumab (DIAN-TU)
Autosomal dominant AD II Inclusion and outcome
evaluation
Inclusion and outcome
evaluation
NCT01760005
III
Crenezumab Prodromal autosomal dominant AD
kindred or mild to moderate AD
II Outcome evaluations Inclusion and outcome
evaluations
NCT01998841
NCT02353598
Aducanumab (BIIB037 study,
ENGAGE, EMERGE)
Prodromal or mild AD I – Inclusion and outcome
evaluations
NCT01677572
III NCT02484547
NCT02477800
Ponezumab Cerebral amyloid angiopathy II – – NCT01821118
BAN2401 Early AD II – Inclusion and outcome
evaluations
NCT01767311
CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
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to incur in the same side effects (ARIA) previously reported.
Noteworthy, the enthusiasm for the very promising perspectives
emerging for aducanumab (NCT01677572) and gantenerumab
(NCT02051608 and NCT01760005) may be affected by patient
complains related to the high risk of ARIA, thus reducing their
feeling in the treatment.Without effective biomarkers wewill have
the consequence of further unacceptable delays in finding a cure
for these devastating diseases.
Biomarkers for ARIA will also improve our understanding on
the mechanisms of action and drug efficacy of immunotherapies,
i.e., the decreased Aβ load observed on amyloid-PET (8, 11, 12,
22) and the associated positive effects on downstream markers of
neurodegeneration (11, 12, 48).
Although the study of CSF and/or imaging biomarkers for
ARIA is matter of current active investigation (50), as highlighted
in this review, more research is obviously needed.
The validation of biomarkers for ARIA will necessarily imply
a multidisciplinary approach and the more strict collaboration
between pharmaceutical companies leading immunotherapy tri-
als, clinicians, basic researchers from academy, research societies
and regulatory authorities.
In the near future, the comprehension of the physiopathological
mechanisms of ARIA and the discovery of early biomarkers will
represent an important challenge in order to ensure safe and
beneficial effects of immunotherapy (16, 17, 49). Therapeutic
implications for CSF anti-Aβ autoantibodies biomarker would
be of immediate application, representing a unique benefit of
DMT efficacy compared to other more expensive techniques
such as amyloid-PET. CSF withdrawal is in effect a common and
minimally invasive diagnostic procedure widely used in clinical
trials (Table 1). The opportunity to implement this biomarker
should thus be taken in serious consideration, particularly in the
suspicious of ARIA.
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